Search

Hutchison China MediTech Ltd ADR

Aperta

SettoreSettore sanitario

12.01 4.25

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.52

Massimo

12.42

Metriche Chiave

By Trading Economics

Entrata

7M

8M

Vendite

3.7M

139M

P/E

Media del settore

115.5

68.51

Margine di Profitto

5.724

Dipendenti

1,790

EBITDA

18M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+22.82% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

95M

2B

Apertura precedente

7.76

Chiusura precedente

12.01

Notizie sul Sentiment di mercato

By Acuity

100%

0%

329 / 340 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 ago 2026, 23:56 UTC

News

Clear Secure Inc launched a Corporate Memberships program to improve business travel, combining services like CLEAR+ and TSA PreCheck. Shares are trading higher after the announcement.

6 ago 2026, 23:56 UTC

News

Shares declined after-hours despite JP Morgan raising price target to $545.

6 ago 2026, 23:52 UTC

News

First Solar supports Section 232 action on polysilicon imports, benefiting U.S. manufacturing. Shares have moved sharply higher in after-market trading.

6 ago 2026, 23:51 UTC

News

The Invesco Currencyshares Japanese Yen Trust is lower in after-market hours, reflecting broader market movements amid ongoing U.S. and Japan currency interventions.

6 ago 2026, 23:51 UTC

News

LeMaitre Vascular Inc shares declined in after-market trading, nearing the lower end of their one-month range amid broader market volatility from Middle East supply concerns.

6 ago 2026, 23:51 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

6 ago 2026, 23:51 UTC

News

Fox Factory Holding Corp reported Q2 sales of $358.1 million, exceeding expectations. The company raised its full-year guidance, and shares advanced in after-market trading.

6 ago 2026, 23:51 UTC

News
Social Media

Twilio Inc reported second-quarter revenue of $1.50 billion, exceeding estimates. Shares are trading sharply higher in after-market hours following the strong results.

6 ago 2026, 23:51 UTC

News
Social Media

Indie Semiconductor reports second-quarter revenue of $64 million, exceeding estimates. Shares are trading higher in after-market hours on positive guidance for Q3.

6 ago 2026, 23:51 UTC

News
Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

6 ago 2026, 23:51 UTC

News
Social Media

Onto Innovation shares rose in after-market trading following record revenue of $343 million and adjusted EPS of $1.93, both exceeding analyst expectations.

6 ago 2026, 23:51 UTC

News
Social Media

Airbnb Inc. reported second-quarter revenue of $3.61 billion, exceeding estimates. Shares rose significantly in after-market trading, despite earlier pulling back from a session high.

6 ago 2026, 23:46 UTC

News
Social Media

Republic Services reported strong second-quarter earnings and raised full-year adjusted EPS guidance. The stock was trading roughly flat in after-market hours.

6 ago 2026, 23:46 UTC

News

McDonald's shares are lower in after-market trading as CEO Chris Kempczinski discusses challenges with the company's value menu strategy and execution issues.

6 ago 2026, 23:42 UTC

Social Media
News

DraftKings shares are lower in after-market hours following a net loss of $67.6 million and revenue that fell short of estimates.

6 ago 2026, 23:41 UTC

News
Social Media

MP Materials reported second-quarter revenue of $108.5 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings announcement.

6 ago 2026, 23:41 UTC

News
Social Media

Doximity reported fiscal Q1 revenue of $156.6 million, exceeding expectations. The company raised its FY2027 revenue guidance, driving shares higher in after-hours trading.

6 ago 2026, 23:41 UTC

News

nLIGHT Inc shares are sharply lower in after-market trading following mixed Q2 results and cautious guidance, projecting revenues below analyst expectations.

6 ago 2026, 23:41 UTC

Social Media
Event
News

Dropbox Inc. shares declined in after-market trading despite reporting Q2 revenue of $631.5 million, exceeding expectations. Concerns over stagnant growth contributed to the drop.

6 ago 2026, 23:36 UTC

News

First Business Financial Services Inc shares are higher in after-market hours, positioned near the upper end of their one-month trading range.

6 ago 2026, 23:36 UTC

News

Navient Corp reported second quarter earnings of $0.26 per share, exceeding expectations, but shares are trading lower in after-market hours amid revenue decline.

6 ago 2026, 23:36 UTC

News

Canaccord Genuity maintained its Hold rating on Zillow Group and lowered its price target to $40. Shares are trading roughly flat after market hours.

6 ago 2026, 23:32 UTC

News

Insulet Corp shares are lower in after-market hours following a downgrade to Market Perform by Leerink Partners and a reduced price target of $145.

6 ago 2026, 23:31 UTC

News

Arlo Technologies reported second-quarter revenue of $156 million and raised fiscal year 2026 guidance, contributing to a notable increase in after-market trading.

6 ago 2026, 23:31 UTC

News
Social Media

Akamai Technologies reported second-quarter revenue of $1.1 billion and adjusted EPS of $1.59, both exceeding analyst expectations. The stock is higher in after-market trading.

6 ago 2026, 23:31 UTC

News
Social Media

Figs Inc. reported second-quarter revenues of $196.6 million and raised its full-year growth forecast, contributing to a notable rise in after-market trading.

6 ago 2026, 23:31 UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

6 ago 2026, 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

6 ago 2026, 23:31 UTC

News
Social Media

Sweetgreen Inc. shares fell sharply in after-market trading following a significant net loss and revenue miss in its second-quarter results.

6 ago 2026, 23:31 UTC

News
Social Media

Trade Desk Inc shares declined sharply after reporting second-quarter revenue of $715 million, missing expectations, and providing weak guidance for the third quarter.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

22.82% in crescita

Previsioni per 12 mesi

Media 14.53 USD  22.82%

Alto 16 USD

Basso 13.6 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

1

Acquista

2

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat